BioMarin Pharma (BMRN) Tops Q2 EPS by 25c

BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $1.20, $0.25 better than the analyst estimate of $0.95. Revenue for the quarter came in at $990 million versus the consensus estimate of $939.37 million.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $59 at H.C. Wainwright
• DA Davidson Reiterates Buy Rating on Jack Henry (JKHY) Following Q4 Results
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance